TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of “Hold” from Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been given an average rating of “Hold” by the seven research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $6.60.

A number of research analysts recently commented on the company. HC Wainwright decreased their price objective on TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Needham & Company LLC lowered their price objective on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Morgan Stanley cut TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. BTIG Research cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Thursday, January 22nd.

TScan Therapeutics Stock Up 4.6%

NASDAQ TCRX opened at $1.02 on Thursday. TScan Therapeutics has a 52 week low of $0.88 and a 52 week high of $2.57. The company has a quick ratio of 6.44, a current ratio of 6.44 and a debt-to-equity ratio of 0.23. The business’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.45. The firm has a market cap of $57.89 million, a PE ratio of -0.91 and a beta of 1.04.

Insider Buying and Selling

In related news, major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of the business’s stock in a transaction on Friday, December 19th. The shares were bought at an average price of $0.90 per share, for a total transaction of $72,062.10. Following the acquisition, the insider directly owned 7,937,416 shares in the company, valued at $7,143,674.40. This trade represents a 1.02% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders acquired 161,801 shares of company stock worth $145,621. Insiders own 4.35% of the company’s stock.

Institutional Trading of TScan Therapeutics

Large investors have recently made changes to their positions in the company. Boothbay Fund Management LLC boosted its stake in TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after acquiring an additional 8,121 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of TScan Therapeutics by 6.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after purchasing an additional 9,676 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in shares of TScan Therapeutics in the 2nd quarter valued at about $26,000. Letko Brosseau & Associates Inc. boosted its position in shares of TScan Therapeutics by 24.4% in the 2nd quarter. Letko Brosseau & Associates Inc. now owns 95,875 shares of the company’s stock valued at $139,000 after purchasing an additional 18,775 shares during the period. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in TScan Therapeutics during the 2nd quarter worth approximately $29,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.